Rare diseases offer insights into autism spectrum disorders. Preliminary laboratory studies suggest new biological targets for intervention

Harv Ment Health Lett. 2009 Apr;25(10):3.
No abstract available

MeSH terms

  • Animals
  • Autistic Disorder / drug therapy
  • Autistic Disorder / genetics*
  • Drosophila
  • Fragile X Mental Retardation Protein / genetics
  • Fragile X Syndrome / drug therapy
  • Fragile X Syndrome / genetics
  • Glutamic Acid / drug effects
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Methyl-CpG-Binding Protein 2 / genetics
  • Mice
  • Protein Kinases / drug effects
  • Protein Kinases / genetics
  • Rett Syndrome / drug therapy
  • Rett Syndrome / genetics
  • Sirolimus / therapeutic use
  • TOR Serine-Threonine Kinases
  • Tuberous Sclerosis / drug therapy
  • Tuberous Sclerosis / genetics
  • Tuberous Sclerosis Complex 1 Protein
  • Tuberous Sclerosis Complex 2 Protein
  • Tumor Suppressor Proteins / genetics

Substances

  • FMR1 protein, human
  • Immunosuppressive Agents
  • Methyl-CpG-Binding Protein 2
  • Tuberous Sclerosis Complex 1 Protein
  • Tuberous Sclerosis Complex 2 Protein
  • Tumor Suppressor Proteins
  • Fragile X Mental Retardation Protein
  • Glutamic Acid
  • Protein Kinases
  • MTOR protein, human
  • mTOR protein, mouse
  • TOR Serine-Threonine Kinases
  • Sirolimus